Upstream Bio announces positive results from the Phase 2 VIBRANT trial evaluating Verekitug for CRSwNP treatment.
Verekitug demonstrated statistically significant and clinically meaningful reductions in nasal polyp score and congestion.
The trial showed improvements in key secondary endpoints and a generally well-tolerated safety profile.
Positive Results
VIBRANT trial of Verekitug showed significant reductions in nasal polyp score and congestion, meeting primary and key secondary endpoints.
Safety Profile
Verekitug demonstrated a well-tolerated safety profile with no serious adverse events observed.
Clinical Potential
Verekitug's potent targeting of the TSLP receptor may offer distinct clinical benefits in CRSwNP treatment.
- The Phase 2 VIBRANT trial highlights Verekitug's potential to advance the standard of care in CRSwNP treatment.
- Results suggest Verekitug's clinical effect and extended dosing could address unmet needs in respiratory diseases like severe asthma.
The positive results from the VIBRANT trial position Verekitug as a promising treatment option for CRSwNP, with the potential to impact the standard of care in respiratory diseases.